SEE-DRUG
ESTABLISHMENT OF A CENTRE OF EXCELLENCE FOR STRUCTURE-BASED DRUG TARGET CHARACTERIZATION: STRENGTHENING THE RESEARCH CAPACITY OF SOUTH-EASTERN EUROPE
| Coordinatore | UNIVERSITY OF PATRAS
Organization address
address: UNIVERSITY CAMPUS RIO PATRAS contact info |
| Nazionalità Coordinatore | Greece [EL] |
| Totale costo | 3˙586˙420 € |
| EC contributo | 3˙199˙527 € |
| Programma | FP7-REGPOT
Specific Programme "Capacities": Research potential of Convergence Regions |
| Code Call | FP7-REGPOT-2011-1 |
| Funding Scheme | CSA-SA |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF PATRAS
Organization address
address: UNIVERSITY CAMPUS RIO PATRAS contact info |
EL (RIO PATRAS) | coordinator | 3˙199˙527.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'SEE-DRUG’s Major Aim is to strengthen and broaden the scientific reach and socio-economic impact of the University of Patras (UPAT) through the creation of a Regional Centre of Excellence for Structural Biology that emphasizes the characterization and development of bioactive molecules with therapeutic potential. SEE-DRUG takes advantage of UPAT’s pivotal strength and growth potential of Structural Biology and combines it with high-quality, multidisciplinary scientific expertise in Chemistry, Pharmacology, Biology & Bioinformatics. The SEE-DRUG project will enable: (a) the Protein Production group to efficiently produce and characterize protein drug-targets for structural analysis and drug development efforts, (b) the Structural Biology group to perform high-resolution structure determination, through time- and cost-effective NMR-based, cutting-edge techniques, and (c) the Pharmacology group to characterize lead therapeutic molecules in a comprehensive array of in vitro, ex vivo and in vivo systems. The long-term benefits of SEE-DRUG implementation will manifest on 3 levels: (a) the pooling of scientific expertise & the upgrading of infrastructure within UPAT, (b) the optimal integration of UPAT’s Structural Biology in ERA through the establishment of long-lasting partnerships, (c) the creation of a solid scientific platform that will become a pole for therapeutic biomolecule-oriented Structural Biology in Greece and in SouthEastern EU, and (d) the exchange of expertise (via twinning actions with 8 EU partnering organizations) and the building of networks with other scientists and technology end-users at a regional or local level, including the bio-pharmaceutical industry. Last, but not least, such a state-of-the-art Centre will create a number of positions for highly skilled scientists and thus enhance scientific and economic growth both at a local and at a regional level, which will hopefully be sustained for years to come.'